Evidence map›Paper›PMID 33862299›Full record

SynthesisWorld neurosurgery2021

Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.

John P Andrews, Rushikesh S Joshi, Matheus P Pereira, Taemin Oh, Alexander F Haddad, Kaitlyn M Pereira, Robert C Osorio, Kevin C Donohue, Zain Peeran, Sweta Sudhir and 7 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World neurosurgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

John P AndrewsDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Rushikesh S JoshiDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Matheus P PereiraDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Taemin OhDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Alexander F HaddadDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Kaitlyn M PereiraDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Robert C OsorioDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Kevin C DonohueDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Zain PeeranDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Sweta SudhirDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Saket JainDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Angad BeniwalDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Ashley S ChopraDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Narpal S SandhuDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Tarik TihanDepartment of Pathology, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Lewis BlevinsDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Manish K AghiDepartment of Neurological Surgery, University of California, San Francisco, School of Medicine, San Francisco, California, USA. Electronic address: Manish.Aghi@ucsf.edu.

Funding

Tumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2M
NINDS NIH HHS R01 NS079697
6 · The paper itself

Abstract

objectiveThe 2017 World Health Organization classification of pituitary adenomas identified the plurihormonal PIT-1-positive (PP1) adenoma as a distinct subtype. The reported data suggest that PP1 adenomas encompass the former class of silent subtype 3 (SS3) adenomas and might have an aggressive phenotype. In the present study, we summarized the current clinical data on PP1 and SS3 adenomas and compared the reported data with the data from a single institutional cohort.

methodsMedline and Google Scholar were searched from 1990 to 2020 for clinical series of PP1 and SS3 adenomas in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Studies were included if they had reported pituitary pathology as PP1 or SS3 adenomas and had reported the clinical outcomes after surgical intervention. To better define the PP1 phenotype compared with non-PP1 adenomas, we also reviewed the adenomas treated surgically at our institution from 2012 to 2019.

resultsOf all the tumors reported in the studies as PP1 or SS3, 99% were macroadenomas and 18% were giant adenomas (>4 cm). Of the reported patients, 31.8% had received radiotherapy, and 22.9% had undergone multiple surgeries for their pituitary tumor. In our single-center experience, 20 patients had an adenoma that met the criteria for a PP1 adenoma. Compared with the 1146 non-PP1 tumors, the PP1 tumors did not show statistically significant differences in the extent of resection, size, number of previous surgeries, future reoperations, rate of radiotherapy, p53 staining, or MIB-1 labeling index.

conclusionsThe findings from the present large, single-center study comparing PP1 and non-PP1 adenomas do not suggest that PP1 tumors are more aggressive. Further work is warranted to identify the pathologic subtypes of pituitary adenomas that are consistently more clinically aggressive.

Indexed as

AdenomaAdultFemaleHumansMaleMiddle AgedNeoplasm InvasivenessPituitary NeoplasmsAtypical pituitary adenomaPIT-1Pituitary adenomaPlurihormonalSilent subtype 3 adenoma

Identifiers

PMID33862299
PMCPMC9466646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.